IMMUNIC INC(NASDAQ:IMUX) stock News

IMUX Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Proposed Public Offering

8 months ago - By: Immunic, Inc.

Immunic, Inc. to Participate in Investor Conference in December

24 days ago - By: Immunic, Inc.

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

a month ago - By: Immunic, Inc.

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

a month ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

2 months ago - By: Immunic, Inc.

Immunic to Participate in Investor, Scientific and Industry Conferences in June

2 months ago - By: Benzinga - Mentions: HBIO STRM RGC HCTI ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

2 months ago - By: Benzinga - Mentions: SPRO ABP VEEV NTLA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

3 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Industry Conferences in May

3 months ago - By: Immunic, Inc.

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

3 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

3 months ago - By: Immunic, Inc.

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

4 months ago - By: Immunic, Inc.

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

5 months ago - By: Immunic, Inc.

Immunic to Participate in Scientific and Investor Conferences in March

5 months ago - By: Immunic, Inc.

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

5 months ago - By: Immunic, Inc.

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

5 months ago - By: Immunic, Inc.

Immunic to Participate in Investor and Scientific Conferences in February

6 months ago - By: Immunic, Inc.

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

8 months ago - By: Immunic, Inc.

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

8 months ago - By: Immunic, Inc.

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Immunic, Inc.

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

9 months ago - By: Immunic, Inc.

IMMUNIC INC (IMUX) Stock News

IMUX Latest News, Press Relases and Analysis

Immunic, Inc. Announces Proposed Public Offering

Immunic, Inc. to Participate in Investor Conference in December

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

12 Health Care Stocks Moving In Thursday's Intraday Session

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

12 Health Care Stocks Moving In Wednesday's After-Market Session

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November